Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MBTPS1 | Q14703 | 20/20 | 1.00 |
| ▸ | F10 | P00742 | 1/20 | 1.00 |
| ▸ | PLAU | P00749 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29363326 | 1.00 | MBTPS1 (1.00) | MBTPS1F10PLAU | |
| SCHEMBL21853304 | 1.00 | MBTPS1 (1.00) | MBTPS1F10PLAU | |
| Hydrochloric Acid SCHEMBL20541310 | 0.99 | MBTPS1 (0.98) | MBTPS1F10PLAU | |
| Hydrochloric Acid SCHEMBL20541308 | 0.99 | MBTPS1 (0.98) | MBTPS1F10PLAU | |
| SCHEMBL21853303 | 0.83 | MBTPS1 (0.71) | MBTPS1F10PLAU | |
| SCHEMBL4210498 | 0.73 | MBTPS1 (0.59) | MBTPS1F10PLAU | |
| SCHEMBL4919198 | 0.67 | TACR1 (0.52) | MBTPS1F10PLAU | |
| SCHEMBL340465 | 0.67 | SLC6A2 (0.51) | MBTPS1F10PLAU | |
| SCHEMBL7262616 | 0.66 | MBTPS1 (0.52) | MBTPS1F10PLAU | |
| SCHEMBL476886 | 0.65 | SLC6A2 (0.60) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112773791-B | Application of S1P inhibitor in preparation of medicines for treating neurodegenerative diseases | 徐州医科大学 | 2022-09-23 | — | — | CN | claimed |
| CN-112773791-A | Application of S1P inhibitor in preparation of medicines for treating neurodegenerative diseases | 徐州医科大学 | 2021-05-11 | — | — | CN | claimed |
| EP-3612174-B1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH REDUCED CFTR FUNCTION | INST NAT SANTE RECH MED (FR) | 2023-02-22 | — | — | EP | disclosed |
| US-11534423-B2 | Methods and compositions for improving exercise endurance, performance, or tolerance | WASHINGTON UNIVERSITY (US) | 2022-12-27 | — | — | US | disclosed |
| US-11458118-B2 | Methods and pharmaceutical compositions for the treatment of diseases associated with reduced CFTR function | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2022-10-04 | — | — | US | disclosed |
| CN-112773791-B | Application of S1P inhibitor in preparation of medicines for treating neurodegenerative diseases | 徐州医科大学 | 2022-09-23 | — | — | CN | disclosed |
| US-11202795-B2 | Means and methods for treatment of early-onset Parkinson's disease | VIB VZW (BE) | 2021-12-21 | — | — | US | disclosed |
| CN-112773791-A | Application of S1P inhibitor in preparation of medicines for treating neurodegenerative diseases | 徐州医科大学 | 2021-05-11 | — | — | CN | disclosed |
| US-20200215032-A1 | METHODS AND COMPOSITIONS FOR IMPROVING EXERCISE ENDURANCE, PERFORMANCE, OR TOLERANCE | WASHINGTON UNIVERSITY (US) | 2020-07-09 | — | — | US | disclosed |
| US-20200121642-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH REDUCED CFTR FUNCTION | UNIVERSITÉ DE BRETAGNE OCCIDENTALE (FR) | 2020-04-23 | — | — | US | disclosed |
| EP-3612174-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH REDUCED CFTR FUNCTION | Institut National de la Sante et de la Recherche Medicale (INSERM) (FR) | 2020-02-26 | — | — | EP | disclosed |
| US-20110053947-A1 | Arylchalcogenoarylalkyl-substituted imidazolidine-2,4-diones, process for preparation thereof, medicaments comprising these compounds and use thereof | SANOFI-AVENTIS (FR) | 2011-03-03 | — | — | US | disclosed |
| US-20110053947-A1 | Arylchalcogenoarylalkyl-substituted imidazolidine-2,4-diones, process for preparation thereof, medicaments comprising these compounds and use thereof | SANOFI-AVENTIS (FR) | 2011-03-03 | — | — | US | disclosed |
| US-20110046185-A1 | Arylchalcogenoarylalkyl-substituted imidazolidine-2,4-diones, process for preparation thereof, medicaments comprising these compounds and use thereof | SANOFI-AVENTIS (FR) | 2011-02-24 | — | — | US | disclosed |
| US-20110046185-A1 | Arylchalcogenoarylalkyl-substituted imidazolidine-2,4-diones, process for preparation thereof, medicaments comprising these compounds and use thereof | SANOFI-AVENTIS (FR) | 2011-02-24 | — | — | US | disclosed |
| US-20110046105-A1 | Heterocycle-substituted imidazolidine-2,4-diones, process for preparation thereof, medicaments comprising them and use thereof | SANOFI-AVENTIS (FR) | 2011-02-24 | — | — | US | disclosed |
| US-20110046105-A1 | Heterocycle-substituted imidazolidine-2,4-diones, process for preparation thereof, medicaments comprising them and use thereof | SANOFI-AVENTIS (FR) | 2011-02-24 | — | — | US | disclosed |
| US-20100249097-A1 | NOVEL SUBSTITUTED TETRAHYDRONAPHTHALENES, PROCESS FOR THE PREPARATION THEREOF AND THE USE THEREOF AS MEDICAMENTS | SANOFI-AVENTIS (FR) | 2010-09-30 | — | — | US | disclosed |
| US-20100249097-A1 | NOVEL SUBSTITUTED TETRAHYDRONAPHTHALENES, PROCESS FOR THE PREPARATION THEREOF AND THE USE THEREOF AS MEDICAMENTS | SANOFI-AVENTIS (FR) | 2010-09-30 | — | — | US | disclosed |
| WO-2010000401-A1 | USE OF SUBSTITUTED PYRIDINONE CARBOXYLIC ACID DERIVATES FOR PRODUCING PHARMACEUTICALS FOR THE TREATMENT OF DYSLIPIDEMIA | SANOFI-AVENTIS (FR) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11534423-B2 | Methods and compositions for improving exercise endurance, performance, or tolerance | S1PR1, S1PR2, S1PR3 | MBTPS1 1890/4885F10 4612/4885PLAU 3383/4885 |
| US-20110046185-A1 | Arylchalcogenoarylalkyl-substituted imidazolidine-2,4-diones, process for preparation thereof, medicaments comprising these compounds and use thereof | PGC, LIPC, CEL | MBTPS1 4375/4885F10 879/4885PLAU 3340/4885 |
| US-20110046105-A1 | Heterocycle-substituted imidazolidine-2,4-diones, process for preparation thereof, medicaments comprising them and use thereof | GIPR, DDC, PGC | MBTPS1 4589/4885F10 560/4885PLAU 3477/4885 |
| US-20100249097-A1 | NOVEL SUBSTITUTED TETRAHYDRONAPHTHALENES, PROCESS FOR THE PREPARATION THEREOF AND THE USE THEREOF AS MEDICAMENTS | DHPS, CYP11B2, CYP11B1 | MBTPS1 2453/4885F10 2485/4885PLAU 2744/4885 |
| US-20110053947-A1 | Arylchalcogenoarylalkyl-substituted imidazolidine-2,4-diones, process for preparation thereof, medicaments comprising these compounds and use thereof | PGC, LIPC, CEL | MBTPS1 4395/4885F10 878/4885PLAU 3233/4885 |
| US-11202795-B2 | Means and methods for treatment of early-onset Parkinson's disease | PINK1, PARK7, SNCA | MBTPS1 1637/4885F10 4438/4885PLAU 2691/4885 |
| US-20200215032-A1 | METHODS AND COMPOSITIONS FOR IMPROVING EXERCISE ENDURANCE, PERFORMANCE, OR TOLERANCE | S1PR1, S1PR2, S1PR3 | MBTPS1 1890/4885F10 4612/4885PLAU 3383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.